Please cite this paper as: Reisinger et al. Safety and tolerability of a 6-week course of oseltamivir prophylaxis for seasonal influenza in children. Influenza and Other Respiratory Viruses DOI: 10.1111/j.1750-2659.2012.00367.x.
In an open-label study, 49 children aged 1–12 years received oseltamivir (30–75 mg once daily depending on bodyweight) for 6 weeks for influenza prophylaxis. Seventeen participants reported 22 adverse events (AEs); in three participants, AEs were considered probably drug related (nausea or vomiting). No serious AEs were reported. The tolerability profile was similar to pooled safety data from treatment studies (duration of 5 days) in children.